DE60130014T2 - Verfahren zur herstellung der b-form von nateglinid-kristallen - Google Patents
Verfahren zur herstellung der b-form von nateglinid-kristallen Download PDFInfo
- Publication number
- DE60130014T2 DE60130014T2 DE60130014T DE60130014T DE60130014T2 DE 60130014 T2 DE60130014 T2 DE 60130014T2 DE 60130014 T DE60130014 T DE 60130014T DE 60130014 T DE60130014 T DE 60130014T DE 60130014 T2 DE60130014 T2 DE 60130014T2
- Authority
- DE
- Germany
- Prior art keywords
- crystals
- nateglinide
- type crystals
- type
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 97
- 229960000698 nateglinide Drugs 0.000 title claims abstract description 41
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 title claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 230000009466 transformation Effects 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- -1 nateglinide hydrates Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000012453 solvate Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000324375 | 2000-10-24 | ||
| JP2000324375 | 2000-10-24 | ||
| PCT/JP2001/009293 WO2002034713A1 (en) | 2000-10-24 | 2001-10-23 | Process for producing b-form nateglinide crystal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60130014D1 DE60130014D1 (de) | 2007-09-27 |
| DE60130014T2 true DE60130014T2 (de) | 2008-05-08 |
Family
ID=18801920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60130014T Expired - Lifetime DE60130014T2 (de) | 2000-10-24 | 2001-10-23 | Verfahren zur herstellung der b-form von nateglinid-kristallen |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030229249A1 (enExample) |
| EP (1) | EP1334964B1 (enExample) |
| JP (1) | JP4225057B2 (enExample) |
| KR (1) | KR100810930B1 (enExample) |
| CN (1) | CN100422143C (enExample) |
| AT (1) | ATE370115T1 (enExample) |
| AU (1) | AU2001296001A1 (enExample) |
| BR (1) | BR0114846A (enExample) |
| CA (1) | CA2426745C (enExample) |
| CY (1) | CY1106839T1 (enExample) |
| DE (1) | DE60130014T2 (enExample) |
| DK (1) | DK1334964T3 (enExample) |
| ES (1) | ES2288997T3 (enExample) |
| MX (1) | MXPA03003575A (enExample) |
| PT (1) | PT1334964E (enExample) |
| RU (1) | RU2275354C2 (enExample) |
| TW (1) | TWI293290B (enExample) |
| WO (1) | WO2002034713A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4116801A (en) * | 2000-03-17 | 2001-09-24 | Ajinomoto Kk | Drugs for complications of diabetes and neuropathy and utilization thereof |
| ES2290173T3 (es) * | 2000-10-18 | 2008-02-16 | Ajinomoto Co., Inc. | Procedimiento para la preparacion de acilfenilalaninas. |
| JP4114200B2 (ja) * | 2000-10-18 | 2008-07-09 | 味の素株式会社 | ナテグリニド結晶の製造方法 |
| AU2001296000A1 (en) * | 2000-10-24 | 2002-05-27 | Ajinomoto Co., Inc. | Nateglinide-containing hydrophilic drug preparations |
| BR0114896A (pt) * | 2000-10-24 | 2003-08-12 | Ajinomoto Kk | Preparação contendo nateglinida, e, método para produzir a mesma |
| EP1496048A4 (en) * | 2002-04-15 | 2006-08-02 | Ajinomoto Kk | NEW NATEGLINID CRYSTAL |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7420084B2 (en) * | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| AU2003253971A1 (en) * | 2002-07-18 | 2004-02-09 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| ES2279921T3 (es) * | 2003-11-26 | 2007-09-01 | A.M.S.A. Anonima Materie Sintetiche E Affini S.P.A. | Procedimiento para la preparacion de nateglinida preferentemente en forma b. |
| US20060004102A1 (en) * | 2004-05-07 | 2006-01-05 | Shlomit Wizel | Polymorphic forms of nateglinide |
| WO2005110395A1 (en) * | 2004-05-19 | 2005-11-24 | University Of South Carolina | System and device for magnetic drug targeting with magnetic drug carrier particles |
| WO2005113485A2 (en) * | 2004-05-20 | 2005-12-01 | Dr. Reddy's Laboratories Ltd. | Stable nateglinide form b compositions |
| US7425648B2 (en) | 2005-01-03 | 2008-09-16 | A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. | Process for the preparation of nateglinide, preferably in B-form |
| CN101111266A (zh) * | 2005-01-31 | 2008-01-23 | 味之素株式会社 | 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物 |
| WO2007135533A1 (en) * | 2006-05-23 | 2007-11-29 | Aurobindo Pharma Limited | Process for preparing nateglinide b-type crystals |
| KR100837843B1 (ko) * | 2006-12-26 | 2008-06-13 | 씨제이제일제당 (주) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 |
| US9150499B2 (en) | 2010-06-14 | 2015-10-06 | Cipla Limited | Process for the preparation of nateglinide |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| SG11201407300VA (en) | 2012-05-07 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of neurological disorders |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| WO2013168021A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| CA2873084A1 (en) * | 2012-05-08 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| NZ701832A (en) | 2012-05-23 | 2016-08-26 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
| JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
| SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| AU2013311349A1 (en) | 2012-09-08 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| SG11201706952VA (en) | 2014-09-26 | 2017-10-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
| EP3201168B1 (en) | 2014-09-29 | 2020-03-18 | Cellix Bio Private Limited | Compounds and compositions for the treatment of multiple sclerosis |
| AU2014414316B2 (en) | 2014-10-27 | 2020-04-09 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| CN104402756B (zh) * | 2014-11-27 | 2016-08-31 | 天方药业有限公司 | 一种高纯度那格列奈的制备方法 |
| WO2016088132A1 (en) | 2014-12-01 | 2016-06-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| JP6679616B2 (ja) | 2015-01-06 | 2020-04-22 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 炎症及び疼痛の治療のための組成物及び方法 |
| CN109369443A (zh) * | 2018-11-05 | 2019-02-22 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种新的那格列奈h晶型的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| AU615966B2 (en) * | 1987-12-04 | 1991-10-17 | Takeda Chemical Industries Ltd. | Crystals of cephem hydrochloride |
| DE10199058I2 (de) | 1991-07-30 | 2006-04-27 | Alcm Co | Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung |
| US5463116A (en) | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| PT1586314E (pt) * | 1996-11-15 | 2011-07-01 | Ajinomoto Kk | Composição de comprimidos de nateglinida |
| US6844006B1 (en) * | 1999-07-09 | 2005-01-18 | Pennfield Oil Company | Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions |
| PT1616561E (pt) * | 1999-12-28 | 2008-07-09 | Ajinomoto Kk | Preparação antidiabética para administração oral |
| AU4116801A (en) * | 2000-03-17 | 2001-09-24 | Ajinomoto Kk | Drugs for complications of diabetes and neuropathy and utilization thereof |
| JP4114200B2 (ja) * | 2000-10-18 | 2008-07-09 | 味の素株式会社 | ナテグリニド結晶の製造方法 |
| ES2290173T3 (es) * | 2000-10-18 | 2008-02-16 | Ajinomoto Co., Inc. | Procedimiento para la preparacion de acilfenilalaninas. |
| BR0114896A (pt) * | 2000-10-24 | 2003-08-12 | Ajinomoto Kk | Preparação contendo nateglinida, e, método para produzir a mesma |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
-
2001
- 2001-10-23 DE DE60130014T patent/DE60130014T2/de not_active Expired - Lifetime
- 2001-10-23 AT AT01976819T patent/ATE370115T1/de active
- 2001-10-23 DK DK01976819T patent/DK1334964T3/da active
- 2001-10-23 BR BR0114846-0A patent/BR0114846A/pt not_active IP Right Cessation
- 2001-10-23 MX MXPA03003575A patent/MXPA03003575A/es active IP Right Grant
- 2001-10-23 CN CNB018212999A patent/CN100422143C/zh not_active Expired - Fee Related
- 2001-10-23 PT PT01976819T patent/PT1334964E/pt unknown
- 2001-10-23 KR KR1020037005671A patent/KR100810930B1/ko not_active Expired - Fee Related
- 2001-10-23 AU AU2001296001A patent/AU2001296001A1/en not_active Abandoned
- 2001-10-23 EP EP01976819A patent/EP1334964B1/en not_active Expired - Lifetime
- 2001-10-23 RU RU2003111948/04A patent/RU2275354C2/ru not_active IP Right Cessation
- 2001-10-23 JP JP2002537707A patent/JP4225057B2/ja not_active Expired - Fee Related
- 2001-10-23 CA CA002426745A patent/CA2426745C/en not_active Expired - Fee Related
- 2001-10-23 WO PCT/JP2001/009293 patent/WO2002034713A1/ja not_active Ceased
- 2001-10-23 ES ES01976819T patent/ES2288997T3/es not_active Expired - Lifetime
- 2001-10-24 TW TW090126305A patent/TWI293290B/zh not_active IP Right Cessation
-
2003
- 2003-04-24 US US10/421,888 patent/US20030229249A1/en not_active Abandoned
-
2007
- 2007-06-04 US US11/757,769 patent/US7544834B2/en not_active Expired - Fee Related
- 2007-08-28 CY CY20071101136T patent/CY1106839T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2426745A1 (en) | 2003-04-23 |
| TWI293290B (enExample) | 2008-02-11 |
| WO2002034713A1 (en) | 2002-05-02 |
| US7544834B2 (en) | 2009-06-09 |
| JPWO2002034713A1 (ja) | 2004-03-04 |
| EP1334964A4 (en) | 2005-09-28 |
| CA2426745C (en) | 2009-09-15 |
| DK1334964T3 (da) | 2007-09-24 |
| KR100810930B1 (ko) | 2008-03-10 |
| ES2288997T3 (es) | 2008-02-01 |
| BR0114846A (pt) | 2004-02-25 |
| ATE370115T1 (de) | 2007-09-15 |
| MXPA03003575A (es) | 2003-07-14 |
| CN100422143C (zh) | 2008-10-01 |
| JP4225057B2 (ja) | 2009-02-18 |
| AU2001296001A1 (en) | 2002-05-06 |
| US20030229249A1 (en) | 2003-12-11 |
| RU2275354C2 (ru) | 2006-04-27 |
| EP1334964B1 (en) | 2007-08-15 |
| DE60130014D1 (de) | 2007-09-27 |
| CN1483018A (zh) | 2004-03-17 |
| US20070232829A1 (en) | 2007-10-04 |
| KR20030059212A (ko) | 2003-07-07 |
| EP1334964A1 (en) | 2003-08-13 |
| CY1106839T1 (el) | 2012-05-23 |
| PT1334964E (pt) | 2007-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69624657T2 (de) | Verbesserung bei der Herstellung von N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide | |
| DE2112026C3 (de) | 3-Phenyl-l-(2-[pyrrolidinyl-(l)]-äthylamino)-3,4dihydroisochinolin, seine Herstellung und die es enthaltenden medizinischen Zusammensetzungen | |
| DE20216779U1 (de) | Diastereomer angereicherte Niederschläge oder Lösungen eines Sulfonatsalzes von Tamsulosin, erhältlich durch ein Verfahren zur optischen Auftrennung von Tamsulosin und Verbindungen und Zusammensetzungen, die damit verbunden sind | |
| DE1134086B (de) | Verfahren zur Herstellung von analeptisch wirksamen alpha-Aminoisobutyrophenonen und deren Säureadditionssalzen | |
| DE69912773T2 (de) | Nicht hydratisiertes gabapentin polymorph, herstellungsprozess und verwendung zur herstellung von gabapentin pharmazeutischer reinheit. | |
| DE69322820T2 (de) | Verfahren zur Kristallisierung von Aspartam | |
| CH634824A5 (de) | Verfahren zur trennung von diastereomeren 3-(3,4-dibenzyloxyphenyl)-serin. | |
| DE3235372C2 (enExample) | ||
| DE60000661T2 (de) | Eine methode zur herstellung eines polymorphes von einem doxazosin-mesylat | |
| DE2319493C3 (de) | Verfahren zur Gewinnung von optisch aktivem a -Phenylglycin-benzolsulfonat durch optische Aufspaltung von DL- a -Phenylglycinbenzolsulfonat | |
| DE60109212T2 (de) | Herstellung von warfarin-natrium aus warfarin-säure | |
| DE2152550B2 (de) | Verfahren zur Herstellung eines vorwiegend Biuret enthaltenden Gemisches von Autokondensationsprodukten des Harnstoffes | |
| DE2702108C2 (de) | Verfahren zur Abtrennung von Serotonin aus Kaffeewachs | |
| DE10359154A1 (de) | Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I | |
| DE69803636T2 (de) | Verfahren zur Herstellung von (1S,2R)-1-Amino-2-indanol-(R,R)-tartrate methanol Solvat | |
| DE2111196B2 (enExample) | ||
| DE60310734T2 (de) | Verfahren zur Herstellung von Nateglinid in der B-Form | |
| DE813709C (de) | Verfahren zur Herstellung von aromatischen monocyclischen Triaminokohlenwasserstoffen | |
| DE2843040C2 (enExample) | ||
| DE2532308C3 (de) | Verfahren zur Abtrennung von Serotonin aus Kaffeewachs | |
| DE1770351C2 (de) | 2-0-Acyl-clindamycine, Verfahren zu deren Herstellung und diese Verbindungen enthaltende antibiotische Zubereitungen | |
| DE60013599T2 (de) | Herstellung von inogatran-agglomeraten und die verbindung inogatran-anhydrid | |
| DE2224240A1 (de) | Verfahren zur Herstellung von 1- eckige Klammer auf p-(beta-Diäthylaminoäthoxy)-phenyl eckige Klammer zu -l^-diphenyl^-chloräthylen beziehungsweise therapeutisch brauchbaren Salzen desselben | |
| AT164567B (de) | Verfahren zur Gewinnung von Sterinen oder deren Additionsprodukten aus sterinhaltigen Mischungen oder Lösungen | |
| DE809461C (de) | Verfahren zur Herstellung eines Penicillinsalzes mit protrahierter Wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8381 | Inventor (new situation) |
Inventor name: SUMIKAWA, MICHITO, YOKKAICHI-SHI, MIE 510-0885, JP Inventor name: MARUO, MAKOTO, YOKKAICHI-SHI, MIE 510-0885, JP Inventor name: MIYAZAKI, KAZUO, YOKKAICHI-SHI, MIE 510-0885, JP Inventor name: NISHINA, SHIGEHIRO, YOKKAICHI-SHI, MIE 510-088, JP Inventor name: MATSUZAWA, YUKIKO, YOKKAICHI-SHI, MIE 510-0885, JP |
|
| 8364 | No opposition during term of opposition |